The research
Six decades of observation, one landmark study, and a funded trial pipeline. The state of the science — including what nobody can promise you yet.
Withdrawal interruption
Independent teams on three continents keep documenting the same thing: a single dose can switch off opioid withdrawal — without replacing one dependency with another.
Craving that goes quiet
People report the pull going quiet for weeks after treatment — long after the medicine has left the body. The follow-up data backs them.
The metabolite explanation
Ibogaine converts to noribogaine, which clears over weeks. Its receptor activity is the leading account of the extended effect window.
A neuroplasticity signal
In animal models, ibogaine upregulates GDNF in dopamine circuitry — placing it among compounds that may promote rewiring, not just relief.
The evidence ceiling
No adequately powered randomized controlled trial has been completed. Every efficacy claim above rests on observational data.
Institutional momentum
A Nature Medicine publication, state trial funding, and engineered analogs have moved ibogaine to a funded research agenda.
The observational signal is too strong to dismiss — and too unconfirmed to declare settled. Both statements are true at once. That is the position of this entire site.
Read the detail
Wondering if ibogaine fits your situation?
Six questions, two minutes. A straight answer, and we'll tell you honestly if it's no.